(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 44.53% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.24%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Eton Pharmaceuticals's revenue in 2025 is $49,422,000.On average, 2 Wall Street analysts forecast ETON's revenue for 2025 to be $2,106,517,374, with the lowest ETON revenue forecast at $2,091,231,379, and the highest ETON revenue forecast at $2,121,803,369. On average, 2 Wall Street analysts forecast ETON's revenue for 2026 to be $3,072,887,248, with the lowest ETON revenue forecast at $2,815,573,000, and the highest ETON revenue forecast at $3,330,201,496.
In 2027, ETON is forecast to generate $4,001,578,485 in revenue, with the lowest revenue forecast at $3,598,645,022 and the highest revenue forecast at $4,404,511,948.